High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and bFGF

MLA

Andreas-Claudius Hoffmann, et al. “High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and BFGF.” Neoplasia: An International Journal for Oncology Research, vol. 10, no. 7, July 2008, pp. 674–79. EBSCOhost, https://doi.org/10.1593/neo.08292.

APA

Andreas-Claudius Hoffmann, Ryutaro Mori, Daniel Vallbohmer, Jan Brabender, Ellen Klein, Uta Drebber, Stephan E. Baldus, Janine Cooc, Mizutomo Azuma, Ralf Metzger, Arnulf H. Hoelscher, Kathleen D. Danenberg, Klaus L Prenzel, & Peter V. Danenberg. (2008). High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and bFGF. Neoplasia: An International Journal for Oncology Research, 10(7), 674–679. https://doi.org/10.1593/neo.08292

Chicago

Andreas-Claudius Hoffmann, Ryutaro Mori, Daniel Vallbohmer, Jan Brabender, Ellen Klein, Uta Drebber, Stephan E. Baldus, et al. 2008. “High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and BFGF.” Neoplasia: An International Journal for Oncology Research 10 (7): 674–79. doi:10.1593/neo.08292.